JPRN-jRCT2080221515未知2 期
A Randomized Phase II Study of S-1 plus Leucovorin versus S-1 alone in Patients with Gemcitabine-Refractory Advanced Pancreatic Cancer.
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •Patients must be diagnosed as invasive pancreatic ductal carcinoma
- •- Patients with gemcitabine-refractory
- •- Age: 20 years to 79 years
- •- Eastern Cooperetive Oncology Group (ECOG) performance status (PS) of 0 or 1
- •- Sufficient oral intake
- •- Written informed consent
排除标准
- •- Diarrhea
- •- History or presence of severe pulmonary disease
- •- History or presence of severe heart disease
- •- Uncontrolled or severe diabetes
- •- Severe complications(e.g., severe enteritis, severe stomatitis, gastrointestinal ulcer)
研究者
相似试验
已完成
2 期
Phase II study of oral S-1 plus oral leucovorin in patients with previously treated non-small-cell lung cancerPre-treated non-small cell lung cancerJPRN-UMIN000004568Protocol team for S-1 with leucovorin therapy32
Unknown
2 期
S-1/Leucovorin (SL) Versus sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal CancerColorectal CancerNCT01193452Fudan University100
已完成
2 期
Study of S-1 Plus LV for Advanced Gastric CancerGastric CancerNCT02090153Sun Yat-sen University39
已完成
2 期
Phase II study of S-1 plus Leucovorin for metastatic pancreatic adenocarcinoma (JASPAC 03)metastatic pancreatic adenocarcinomaJPRN-UMIN000004958Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)30
已完成
2 期
Phase II study of S-1, leucovorin plus bevacizumab in refractory colorectal cancerColorectal cancerJPRN-UMIN000009083Aichi Cancer Center Hospital, Department of Clinical Oncology30